Assays for the Detection of SARS-CoV-2
AssigneeDiaSorin S.p.A.
InventorsChiara Brambati, Simone Bocchetta, Giulia Minnucci
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents, and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
Claims27
A detectably labeled oligonucleotide that is capable of specifically hybridizing to a SARS-CoV-2 polynucleotide, wherein the nucleotide sequence of said detectably labeled oligonucleotide that is capable of specifically hybridizing to said SARS-CoV-2 polynucleotide is able to hybridize to an oligonucleotide having a nucleotide sequence that consists essentially of the nucleotide sequence atggtgtt, or aatggtgtt, or the respective complements thereof, aacaccat and aacaccatt.
A kit for detecting the presence of SARS-CoV-2 in a clinical sample, wherein said kit comprises:
- (A) one or more oligonucleotide primers capable of amplifying a portion of a SARS-CoV-2 polynucleotide;
- and
- (B) a detectably labeled oligonucleotide that is capable of specifically hybridizing to said amplified portion of said SARS-CoV-2 polynucleotide, wherein the nucleotide sequence of said detectably labeled oligonucleotide that is capable of specifically hybridizing to said SARS-CoV-2 polynucleotide is able to hybridize to an oligonucleotide having a nucleotide sequence that consists essentially of the nucleotide sequence atggtgtt, or aatggtgtt, or the respective complements thereof, aacaccat and aacaccatt.
A method for detecting the presence of SARS-CoV-2 in a clinical sample, wherein said method comprises incubating said clinical sample in vitro in the presence of a detectably labeled oligonucleotide that is capable of specifically hybridizing to a SARS-CoV-2 polynucleotide, wherein the nucleotide sequence of said detectably labeled oligonucleotide that is capable of specifically hybridizing to said SARS-CoV-2 polynucleotide is able to specifically hybridize to an oligonucleotide having a nucleotide sequence that consists essentially of the nucleotide sequence atggtgtt, or aatggtgtt, or the respective complements thereof, aacaccat and aacaccatt;
- wherein said method detects the presence of SARS-CoV-2 in said clinical sample by detecting hybridization between a SARS-CoV-2 polynucleotide in said clinical sample and said detectably labeled oligonucleotide.
Dependencies are inferred from the claim text.